OncoMatch/Clinical Trials/NCT05035147

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer

Is NCT05035147 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies albumin-bound paclitaxel for pancreatic cancer.

Phase 4RecruitingTianjin Medical University Cancer Institute and HospitalNCT05035147Data as of May 2026

Treatment: albumin-bound paclitaxel — This study aims to further observe and evaluate whether the three-week administration of albumin-bound paclitaxel combined with gemcitabine is equivalent to the four-week administration in the treatment of inoperable locally advanced or metastatic pancreatic cancer

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

Hb ≥90 g/L (no blood transfusion within 14 days); ANC ≥1.5×10^9/L; PLT ≥100×10^9/L

Kidney function

Cr ≤1.5x ULN or creatinine clearance rate ≥60 ml/min

Liver function

TBIL <1.5x ULN; ALT and AST ≤3x ULN, <5x ULN if liver metastasis

The main organs are functioning normally, that is, they meet the following standards: Routine blood examination: Hb≥90g/L (no blood transfusion within 14 days); ANC ≥1.5×109/L; PLT ≥100×109/L; Biochemical examination: ALB≥29 g/L (without ALB in 14 days), TBIL <1.5 times the upper limit of normal (ULN); ALT and AST≤3ULN, accompanied by liver metastasis, then ALT and AST<5×ULN; Cr ≤1.5×ULN or creatinine clearance rate ≥60ml/min;

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify